Austin Neuromuscular Center | Austin, TX

Research site

(Unclaimed)

Location

3901 Medical Parkway, Suite 300, Austin, Texas, United States of America

Site insights

Top conditions

Top treatments

AMX0035

Pregabalin

Ravulizumab

Tofersen

Lenabasum

EDG-5506

ABC008

Edaravone

Octagam

M5049

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 31 total trials

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA+)

This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety a...

Active, not recruiting

Multifocal Motor Neuropathy (MMN)

Biological: ARGX-117

Other: Placebo

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) (ASTRALS)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in p...

Active, not recruiting

Amyotrophic Lateral Sclerosis (ALS)

Biological: VHB937

Other: Placebo

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutat...

Active, not recruiting

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

Drug: Tofersen

Drug: Placebo

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)

The purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with IIM who previously p...

Invitation-only

Dermatomyositis

Myositis

Biological: EFG PH20 SC

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Sub...

Active, not recruiting

Inclusion Body Myositis

Drug: ABC008

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatri...

Enrolling

Generalized Myasthenia Gravis

Drug: Inebilizumab

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammator...

Active, not recruiting

Dermatomyositis

Myositis

Biological: EFG PH20 SC

Other: PBO

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis (NIMBLE)

This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with g...

Active, not recruiting

Generalized Myasthenia Gravis

Drug: Pozelimab

Drug: Pozelimab + Cemdisiran

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Enrolling

Idiopathic Inflammatory Myopathies

Sporadic Inclusion Body Myositis (sIBM)

Combination Product: Pozelimab/Cemdisiran

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic i...

Enrolling

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Drug: Nipocalimab

Drug: Placebo

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subject...

Active, not recruiting

Inclusion Body Myositis (IBM)

Drug: Ulviprubart (ABC008)

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON s...

Active, not recruiting

Becker Muscular Dystrophy

Drug: Placebo

Drug: Sevasemten 10 mg